Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 7, 2013 - Issue 5
Submit an article Journal homepage
329
Views
27
CrossRef citations to date
0
Altmetric
Reviews

Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities

Robert P YoungCorrespondence[email protected]
&
Raewyn J HopkinsSchool of Biological Sciences and Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
Pages 533-544 | Published online: 09 Jan 2014

References

  • Young RP, Hopkins RJ, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur. Resp. J. 30(4), 616–622 (2007).
  • Janda S, Park K, Fitzgerald JM, Etminan M, Swiston J. Statins in COPD. Chest 136, 734–743 (2009).
  • Young RP, Hopkins RJ, Eaton TE. Potential benefits of statins on morbidity and mortality in COPD: a review of the evidence. Postgrad. Med. J. 85, 414–421 (2009).
  • Dobler CC, Wong KK, Marks GB. Association between statins and COPD: a systematic review. BMC Pulm. Med. 9, 32 (2009).
  • Young RP, Hopkins RJ, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir. Rev. 18, 222–232 (2009).
  • Sin DD, Man PSF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? the potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107, 1514–1519 (2003).
  • Barnes PJ, Celli BR. Systemic manifestations and co-morbidities in COPD. Eur. Respir. J. 33, 1165–1185 (2009).
  • Agusti A, Edwards LD, Rennard SI et al. Persistent systemic inflammation is associated with poor clinical outcomes in copd: a novel phenotype. PLoS ONE 7(5), e37483 (2012).
  • Cockayne DA, Cheng DT, Waschki B et al. Systemic Biomarkers of neutrophilic inflammation, tissue injury and repair in copd patients with differing levels of disease severity. PLoS ONE 7(6), e38629 (2012).
  • Barr R-G. The epidemiology of vascular dysfunction relating to chronic obstructive pulmonary disease and emphysema. Proc. Am. Thorac. Soc. 8, 522–527 (2011).
  • Fabbri LM, Beghe B, Agusti A. Cardiovascular mechanisms of death in severe COPD exacerbation: time to think and act beyond guidelines. Thorax 66(9), 745–747 (2011).
  • Walter RE, Wilk JB, Larsen MG et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 133, 19–25 (2008).
  • Melbye H, Halvorsen DS, Hartz I et al. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001. Resp. Med. 101, 2541–2549 (2007).
  • Boschetto P, Beghe B, Fabbri LM, Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology 17, 422–431 (2012).
  • Lee T-M, Lin M-S, Chang N-C. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am. J. Cardiol. 101 530–535 (2008).
  • Sin DD, Man SFP. Interleukin 6. Chest 133, 4–6 (2008).
  • Yende S, Waterer GW, Tolley EA et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 61, 10–16 (2006).
  • Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur. Respir. J. 40, 724–741 (2012).
  • Mannino DM, Valvi D, Mullerova H, Tal-Singer R. Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. COPD 9, 359–366 (2012).
  • Hurst JR, Hagan G, Wedzicha JA. Mechanism of statin-associated mortality reduction in COPD. Chest 132, 1409 (2007).
  • Ahmad T, Mabalirajan U, Sharma A et al. Simvastatin improves epithelial dysfunction and airway hyperresponsiveness. From asymmetric dimethyl-arginine to asthma. Am. J. Respir. Cell Mol. Biol. 44, 531–539 (2011).
  • Sin DD, Anthonisen NR, Soriano JB, Augusti AG. Mortality in COPD: role of co-morbidities. Eur. Respir. J. 28, 1245–57 (2006).
  • Sinden NJ, Stockley RA. Systemic inflammation and co-morbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax 65, 930–936 (2010)
  • Yanbeva DG, Detener MA, Creutzberg EC, Woulters EFM. Systemic inflammation in COPD: is genetic susceptibility a key factor. COPD: 3, 51–61 (2006).
  • van Durme YMTA, Verhamme KMC, Aarnoudse A-JLHJ et al. C-Reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 179, 375–382 (2009).
  • Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington County, Maryland. Am. Rev. Respir. Dis. 140, S56–S63 (1989)
  • Olofson J, Skoogh BE, Bake B, Svardsudd K. Mortality related to smoking habits, respiratory symptoms and lung function. Eur. J. Respir. Dis 71, 69–76 (1987).
  • Rasmussen F, Mikkelsen D, Hancox RJ et al. High-sensitive C-reactive protein is associated with reduced lung function in adults. Eur. Respir. J. 33, 382–388 (2009).
  • Gan WQ, Man SFP, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 127, 558–564 (2005).
  • Chang CL, Robinson SC, Mills GD et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 66, 764–768 (2011).
  • Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur. Respir. J. 31, 563–570 (2011).
  • Hoiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Soyseth V. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 66, 775–781 (2011).
  • Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am. J. Med. 121, 219–225 (2008).
  • Guertler C, Christ-Crain M, Zimmerli W, Mueller B, Scheutz P. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur. Respir. J. 37, 1439–1446 (2011).
  • Chang SS, Vaz Fragoso CA, Van Ness PH, Fried LP, Tinetti ME. Association between combined interleukin-6 and C-reactive protein levels and pulmonary function in older women; results from the Women's Health and Aging Studies I and II. J. Am. Geriatr. Soc. 59, 113–119 (2011).
  • Siemes C, Visser LE, Coebergh J-W W et al. C-Reactive protein levels, variation in the C-Reactive protein gene, and cancer risk: the rotterdam study. J. Clin. Oncol. 24(33), 5216–5222 (2006).
  • Cho WCS, Kwan CK, Yau S, So PPF, Poon PCM, Au JSK. The role of inflammation in the pathogenesis of lung cancer. Expert Opin. Ther. Targets 15(9), 1127–1137 (2011).
  • Chaturvedi AK, Caporaso NE, Katki HA et al. C-Reactive protein and risk of lung cancer. J. Clin. Oncol. 28(16), 2719–2726 (2010).
  • Nohria A, Prsic A, Liu PY et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205, 517–521 (2009).
  • Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 333 (7576), 999 (2006).
  • Eurish DT, Majumdar SR. Statins and sepsis – scientifically interesting but clinically inconsequential. J Gen. Intern. Med. 27 (3), 268–269 (2011).
  • Suissa S. Co-Morbidity in COPD: the effects of cardiovascular drug therapies. Respiration 80, 3–7 (2010).
  • Lawes CMM, Thornley S, Young R, et al Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim. Care Respir. 21(1), 35–40 (2012).
  • Lahousse L, Loth DW, Joos GF et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm. Pharmacol. Ther. 26(2), 212–217 (2012).
  • Huang CC, Chan WL, Chen YC et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. Clin. Ther. 33(10), 1365–1370 (2011).
  • Bartziokas K, Papaioannou AI, Minas M et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm. Pharmacol. Ther. 24, 625–631 (2011).
  • Chopra V, Rogers MAM, Buits M et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am. J. Med. 125, 1111–1123. (2012).
  • Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir. Med. 103, 224–229 (2009).
  • Mendendez R, Martinez R, Reyes S et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 64, 587–591(2009).
  • Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 250–255(2007).
  • Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ 184(7), E367–E372 (2012).
  • Vandermeer ML, Thomas AR, Kamimoto L et al. Association between use of statins and mortality among patients hospitalised with laboratory-confirmed influenza virus infection: a multistate study. J. Infect. Dis. 205(1), 13–19 (2012).
  • Young RP, Hopkins RJ. A clinical practice guideline update on the diagnosis and management of stable chronic obstructive pulmonary disease; comment. Ann. Int. Med. 156, 68–69 (2012).
  • Young RP, Hopkins RJ. How the genetics of lung cancer may overlap with COPD. Respirology 16, 1047–1055 (2011).
  • Cohen BH, Diamond EL, Graves CVG et al. A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet 2(8037), 523–526 (1977).
  • de Torres J, Bastarrika G, Wisnivesky JP et al. Assessing the relationship between lung cancer risk and emphysema detected on low dose CT of the chest. Chest 132, 1932–1938 (2007).
  • Wilson DO, Weissfeld JL, Balkan A et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am. J. Respir. Crit. Care Med. 178, 738–744 (2008).
  • Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer independent of age, sex, and smoking history. Eur. Respir. J. 34, 380–386 (2009).
  • Young RP, Hopkins RJ. Diagnosing COPD and targeted lung cancer screening. Eur. Respir. J. 40, 1063–1064 (2012).
  • Young RP, Hopkins RJ, Whittington CF, Hay BA, Epton MJ, Gamble GD. Individual and cumulative effects of GWAS susceptibility loci in lung cancer: associations after sub-phenotyping for COPD. PLoS ONE 6, e16476 (2011)
  • Young RP, Hopkins RJ. COPD and lung cancer linked at a molecular genetic level. Chest 140, 266–267 (2011).
  • Yang IA, Relan V, Wright CM et al. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin. Ther. Targets 15(4), 439–456 (2011).
  • Rooney C, Sethi T. The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer. Respiration 81, 89–104 (2011).
  • Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N. Engl J. Med. 367, 1792–1802 (2012).
  • Young-Jin K, Young-Min K, Kyae HK et al. High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol. Bio. Prev. 21, 2076–2086 (2012).
  • Allin KH, Bojesen SE, Nordestgaard. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol. 27 (13), 2217–2224 (2009).
  • II'yasova D, Colbert LH, Harris TB et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol. Biomarkers Prev. 14, 2413–2418 (2005).
  • Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 11 (12), 886–895 (2011).
  • Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr. Pharma. Des. 18, 3831–3852 (2012).
  • Agusti A, Faner R. Systemic inflammation and co-morbidities in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 9, 43–46 (2012).
  • Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 131, 1282–1288 (2007).
  • Farwell WR, Scranton RE, Lawler EV et al. The association between statins and cancer incidence in a Veterans population. J. Natl Cancer Inst. 100, 134–139 (2008).
  • Karp I, Behlouli H, LeLorier J, Pilote L. Statins and cancer risk. Am. J. Med. 121, 302–309 (2008).
  • van Gestel YRBM, Hoeks SE, Sin DD et al. COPD and cancer mortality: the influence of statins. Thorax 64, 963–967 (2009).
  • Young RP, Hopkins RJ. Effect of statins on cancer in chronic obstructive pulmonary disease. Thorax, 66, 354–355 (2011).
  • Arimura K, Aoshiba K, Tsuji T, Tamaoki J. Chronic low-grade systemic inflammation causes DNA damage in the lungs of mice. Lung 190, 613–620 (2012).
  • Ludman A, Venugopal V, Yellon DM, Hausenloy. Satins and cardioprotection – more than just lipid lowering. Pharmacol. Ther. 122, 30–43 (2009).
  • Patti G, Cannon CP, Murphy SA et al. Clinical benefit of statin pre-treatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 123, 1622–1632 (2011).
  • Strey CH, Young JM, Lainchbury JH et al. Short-term statin therapy improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart 92, 1603–1609 (2006).
  • Young RP, Hopkins RJ. Possible role of statins in COPD-related pulmonary hypertension. Chest 137, 1250–1251 (2010).
  • Shishehbor MH, Brennan ML, Aviles RJ et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108, 426–431 (2003).
  • Young RP, Hopkins RJ. Statins in small airways disease in COPD. Am. J. Resp. Mol. Cell. Biol. 49(3), 501 (2013).
  • Arnaud C, Burger F, Steffens S et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct anti-inflammatory effects of statins. Arterioscler. Thromb. Vasc. Biol. 25, 1231–1236 (2005).
  • Groenewegen KH, Postma DS, Hop WCJ et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 133, 350–357 (2008).
  • Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 186, 982–988 (2012).
  • Ferrari R, Tanni SE, Caram LMO, Correa C, Correa CR, Godoy I. Three-year follow-up of interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir. Res. 14, 24–30 (2013).
  • Thomsen M, Ingebrigtsen TS, Marott JL et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 309, 2353–2361 (2013).
  • Wang MT, Lo YW, Tsai CL et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am. J. Med. 126, 598–606.e2 (2013).
  • McDonald V M, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?Thorax 68, 691–694 (2013).
  • Agusti A, MacNee W. The COPD control panel: towards personalized medicine in COPD. Thorax 68, 687–690 (2013).
  • Young RP, Hopkins RJ. Interleukin-6 and statin therapy: potential role in the management of COPD. Respir. Res. 14, 74–75(2013).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.